GlassScriptPhysician profile
Binod Pokhrel
NPI 1033544465
$3,444.38
in general payments reported to CMS, 2019-2025
23 companies · $471 in 2025
The $471 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $476 · 2021: $590 · 2022: $586 · 2023: $622 · 2024: $417 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,509.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $756.52 | 2019-2025 | Ozempic, Rybelsus |
| Corcept Therapeutics | $477.03 | 2019-2025 | Korlym |
| Lilly USA, LLC | $279.34 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $235.63 | 2020-2025 | Tepezza, Evenity, Prolia |
| Medtronic Minimed, INC. | $209.69 | 2019-2020 | |
| Abbott Laboratories | $193.05 | 2021-2023 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $192.36 | 2021-2023 | Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.76 | 2020-2025 | Jardiance |
| Medtronic, INC. | $179.16 | 2021-2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $112.23 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $111.53 | 2021-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $101.36 | 2020-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $74.14 | 2023 | Imbruvica, Epkinly |
| Sanofi-Aventis U.S. LLC | $66.30 | 2019-2024 | |
| Abbvie INC. | $65.88 | 2021-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $60.57 | 2023-2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $34.60 | 2024-2025 | |
| Kyowa Kirin, INC. | $25.87 | 2024 | Crysvita |
| Ucb, INC. | $25.16 | 2021 | |
| Beta Bionics, INC. | $22.16 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Servier Pharmaceuticals LLC | $16.65 | 2020 | |
| Merck Sharp & Dohme LLC | $12.70 | 2019 | |
| Mckesson Specialty Care Distribution, LLC | $2.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Binod Pokhrel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.